NEURONES financials
NEURONES
Country: FR Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
9695008Y07TSG8SZCG57 Financial statements
(EUR, as reported — unscaled; 91 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Employee benefits expense | €438.8M | €421.6M |
| Raw materials & consumables used | €0 | €0 |
| Operating profit (EBIT) | €75.6M | €77.9M |
| Net finance income / (cost) | €9.5M | €10.2M |
| Profit before tax | €85.1M | €88.1M |
| Income tax expense | €23.2M | €24.9M |
| Profit for the year | €61.9M | €63.2M |
| — attributable to owners | €52.1M | €52.6M |
| — attributable to NCI | €9.8M | €10.7M |
| Total comprehensive income | €61.5M | €63.5M |
| Per share | ||
| Basic EPS | €2.14 | €2.17 |
| Diluted EPS | €2.14 | €2.16 |
| Cash flow statement | ||
| Net cash from operating activities | €71.3M | €84.4M |
| Net cash from investing activities | -€21.2M | -€19.7M |
| Net cash from financing activities | -€35.6M | -€34.5M |
| Dividends paid | €31.6M | €29.1M |
| Proceeds from borrowings | €2.5M | €5.1M |
| Repayments of borrowings | €5.4M | €4.3M |
| Lease liability payments | €8.3M | €8.2M |
| Net change in cash | €14.5M | €30.2M |
| Balance sheet | ||
| Total assets | €749.0M | €725.7M |
| Non-current assets | €140.5M | €137.6M |
| Property, plant & equipment | €29.4M | €28.1M |
| Right-of-use assets | €29.9M | €32.4M |
| Intangible assets & goodwill | €62.7M | €58.2M |
| Current assets | €608.5M | €588.1M |
| Inventories | €18.0K | €267.0K |
| Trade & other receivables | €261.6M | €257.7M |
| Cash & equivalents | €340.8M | €326.5M |
| Total equity | €464.9M | €436.2M |
| — attributable to owners | €400.0M | €378.1M |
| Non-controlling interests | €64.9M | €58.1M |
| Non-current liabilities | €34.1M | €36.9M |
| Long-term borrowings | €760.0K | €2.1M |
| Lease liabilities (non-current) | €25.3M | €27.4M |
| Current liabilities | €250.1M | €252.7M |
| Lease liabilities (current) | €7.6M | €7.6M |
| Trade & other payables | €235.4M | €234.5M |
| Derived metrics | ||
| Operating margin | 8.8% | 9.6% |
| Net margin | 7.2% | 7.8% |
| Return on equity | 13.3% | 14.5% |
| Cash conversion ratio | 1.15× | 1.33× |
| Other reported items | ||
| Adjustments For Decrease Increase In Trade Account Receivable | €179.0K | €141.0K |
| Adjustments For Finance Income Cost | €9.5M | €10.2M |
| Adjustments For Gain Loss On Disposal of Investments In Subsidiaries Joint Ventures and Associates | €0 | €0 |
| Adjustments For Income Tax Expense | €23.2M | €24.9M |
| Adjustments For Sharebased Payments | €4.2M | €5.1M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | €340.2M | €326.0M |
| Cash Flows From Losing Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €152.0K | €137.0K |
| Cash Flows From Used In Operations Before Changes In Working Capital | €99.8M | €100.7M |
| Cash Flows Used In Obtaining Control of Subsidiaries Or Other Businesses Classified As Investing Activities | €4.8M | €2.2M |
| Comprehensive Income Attributable To Noncontrolling Interests | €9.7M | €10.7M |
| Comprehensive Income Attributable To Owners of Parent | €51.8M | €52.8M |
| Current Provisions | €2.7M | €2.0M |
| Current Tax Assets Current | €6.1M | €3.7M |
| Current Tax Liabilities Current | €875.0K | €3.6M |
| Deferred Tax Assets | €6.3M | €6.9M |
| Depreciation Rightofuse Assets | €8.1M | €8.1M |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | €31.6M | €29.1M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | €1.9M | €8.2M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €1.40 | — |
| Dividends Recognised As Distributions To Noncontrolling Interests | €2.0M | €8.2M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€279.0K | €357.0K |
| Equity and Liabilities | €749.0M | €725.7M |
| Finance Income | €11.5M | €12.0M |
| Income Taxes Paid Refund Classified As Operating Activities | €27.8M | €24.8M |
| Increase Decrease In Working Capital | €643.0K | -€8.5M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | -€3.0M | -€6.6M |
| Increase Decrease Through Sharebased Payment Transactions | €4.2M | €5.1M |
| Increase Decrease Through Transactions With Owners | -€30.9M | -€28.8M |
| Increase Decrease Through Treasury Share Transactions | -€1.1M | €303.0K |
| Interest Expense On Lease Liabilities | €870.0K | €907.0K |
| Issued Capital | €9.7M | €9.7M |
| Noncurrent Financial Assets | €12.2M | €12.0M |
| Noncurrent Provisions | €8.1M | €7.4M |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€557.0K | €234.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €230.0K | €0 |
| Other Finance Cost | €1.1M | €912.0K |
| Payments From Changes In Ownership Interests In Subsidiaries | €6.8M | €5.8M |
| Proceeds From Contributions of Noncontrolling Interests | €1.4M | €1.4M |
| Proceeds From Sales Or Maturity of Financial Instruments Classified As Investing Activities | €711.0K | €324.0K |
| Profit Loss From Continuing Operations | €61.9M | €63.2M |
| Purchase of Financial Instruments Classified As Investing Activities | €1.4M | €1.8M |
| Reserve of Exchange Differences On Translation | -€1.9M | — |
| Revenue From Contracts With Customers | €857.2M | €810.4M |
| Revenue From Rendering of Services | €852.1M | €806.0M |
| Revenue From Sale of Goods | €5.1M | €4.4M |
| Services Expense | €316.0M | €287.1M |
| Share Premium | €16.3M | €16.3M |
| Tax Expense Other Than Income Tax Expense | €9.5M | €8.7M |
Methodology
Every line item above is a fact tagged in NEURONES's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.